{"id":"intra-vitreal-injection-of-ranibizumab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-15","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"0.1-0.5","effect":"Retinal detachment"},{"rate":"variable","effect":"Cataract progression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it reduces fluid leakage, prevents abnormal vessel formation, and slows or halts disease progression in conditions affecting the retina and choroid. The intravitreal injection route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:58.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion (branch and central)"},{"name":"Diabetic retinopathy"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT05861466","phase":"PHASE4","title":"Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Diabetic Macular Edema","enrollment":102},{"nctId":"NCT02611778","phase":"PHASE3","title":"Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2015-12-19","conditions":"Age-related Macular Degeneration (AMD)","enrollment":712},{"nctId":"NCT04087746","phase":"PHASE4","title":"Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Minia University","startDate":"2017-01","conditions":"Diabetic Macular Edema","enrollment":400},{"nctId":"NCT01243086","phase":"PHASE2","title":"OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab","status":"COMPLETED","sponsor":"McMaster University","startDate":"2011-03","conditions":"Wet Macular Degeneration","enrollment":10},{"nctId":"NCT02121353","phase":"PHASE1, PHASE2","title":"Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfenex, Inc","startDate":"2013-11","conditions":"Age Related Macular Degeneration (AMD)","enrollment":25},{"nctId":"NCT01363570","phase":"NA","title":"Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes","status":"COMPLETED","sponsor":"McMaster University","startDate":"2012-01","conditions":"Age Related Macular Degeneration","enrollment":70},{"nctId":"NCT01640171","phase":"NA","title":"Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2012-07","conditions":"Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":57},{"nctId":"NCT00857259","phase":"PHASE2","title":"The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration","enrollment":16},{"nctId":"NCT01249937","phase":"PHASE2","title":"Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2011-01","conditions":"Wet Macular Degeneration","enrollment":30},{"nctId":"NCT00811200","phase":"PHASE2, PHASE3","title":"Treatment Of Radiation Retinopathy Trial","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2009-09","conditions":"Uveal Melanoma","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"intra-vitreal injection of Ranibizumab","genericName":"intra-vitreal injection of Ranibizumab","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}